An interventional study of CaCBT and Medication/ Psychotherapy in Depression, Anxiety, sponsored by Peshawar Medical College. Completed at 1 site in Pakistan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-08-16.
Sponsored by Peshawar Medical College · Not applicable, Interventional, and Treatment
CBT for common mental disorders has a strong evidence base in both the USA and the UK. There are wider cultural and linguistic differences between Non Pashtun and Pashtun population of Pakistan and Afghanistan and there is evidence from research to suggest that CBT might need some adaptations when working with clients from non-western background. This study, thus, aims to culturally adapt CBT for common mental disorders for Pashto speaking population in Pakistan and Afghanistan and to test the effectiveness of this adapted CBT through a small scale pilot study.
The study will be carried out using mixed methods; quantitative and qualitative. Qualitative part will consist of structured interview with a minimum of 10-15 patients; carers; and mental health professionals, respectively, using the interview questionnaires. The data will be analysed by systematic content and question analysis which will identify the emerging themes and categories. The data will then be reorganized into wider themes and categories and written for guidelines to culturally adapt therapy manual for common mental disorders.
Quantitative phase will be a RCT involving 40 patients (20 in each arm) to assess the effectiveness of a "CaCBT intervention" for Pashto speaking patients. All those who fulfill the diagnostic criteria of depressive episode or recurrent depressive disorder using ICD 10 RDC, are living near or can easily travel to the psychiatry departments in Peshawar, will be included in the study.
The intervention group of the RCT will receive CaCBT intervention in addition to the treatment as usual (TAU) while the control group receives TAU. The assessment will be carried out at base-line and at the end of therapy (8-12 weeks). Bradford Somatic Inventory (BSI), Hospital Anxiety and Depression Scale (HADS) and Brief Disability Questionnaire (BDQ)/ WHO DAS will be used to measure somatic symptoms, anxiety, depression and disability due to physical and psychological problems, respectively. Schwartz Outcome Scale will be used at follow up to measure the outcome.
8,057 studies on the registry are indexed under Depression; 1,641 are open to participants now.
This study's enrollment of 40 is below the median of 84 across 6,720 interventional studies indexed under Depression.
Browse Depression studies →Peshawar Medical College is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Receiving "CaCBT intervention" in addition to the Treatment as usual
Other: CaCBT · Other: Medication/ Psychotherapy
Receiving Treatment as usual
Other: Medication/ Psychotherapy
Culturally Adapted Cognitive Behaviour Therapy
Medication/ Psychotherapy used as usual
Change in score of Hospital Anxiety and Depression Scale (HADS) from baseline to end of therapy
At baseline and after end of therapy \[after 6 Weekly Sessions (in almost 8 weeks time)\]
Time frame: 2 Months
Change in score of Bradford Somatic Inventory (BSI) from baseline to end of therapy
At baseline and after end of therapy \[after 6 Weekly Sessions (in almost 8 weeks time)\]
Time frame: 2 Months
Change in score of Brief Disability Questionnaire/ WHO DAS from baseline to end of therapy
At baseline and after end of therapy \[after 6 Weekly Sessions (in almost 8 weeks time)\]
Time frame: 2 Months
Schwartz Outcome Scale
At end of therapy
Time frame: 2 Months
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peshawar Medical College